Abstract

Background: The subcutaneous implantable cardioverter defibrillator (S-ICD) represents a major advancement in ICD technology in the last 10 years. During the experience with the 1nd generation of S-ICD, the IAS rate was 4,5% to 25% and with 2nd generation and 3nd generation of S-ICD the IAS rate was 3.1% at one year. Indeed, in the hospital and out of hospital emergency situations in presence of IAS it is mandatory to suspend the shock therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.